Home › Research › Biomarkers
Research Proposal Consciousness Mode Alzheimers
Mart Wijn. Zenodo (CERN European Organization for Nuclear Research), 2026-04-22
Topic: Amyloid, tau and blood-test diagnosis
Abstract The dominant research paradigm for Alzheimer's disease has focused on amyloid-beta plaqueremoval for over three decades, producing no curative therapy despite billions of dollars ofinvestment. This paper presents the Redirection Hypothesis: a framework that reinterprets amyloidaccumulation not as the cause of Alzheimer's disease but as a late-stage downstream consequenceof upstream biological chain failures — in neuroinflammation, epigenetic regulation, mitochondrialfunction, gut-brain signalling, metabolic health, and sleep-dependent glymphatic clearance — thatbegin years or decades before the first plaque is detectable.The framework integrates evidence from twenty-three disciplines and draws on five epidemiologicalnatural experiments (Nigeria versus African Americans, Japanese migration studies, Mediterraneandiet populations, the Finnish FINGER trial, and the Guam neurotoxin pathway) to demonstrate thatenvironmental and lifestyle factors modulate Alzheimer's outcomes independently of geneticpredisposition. A multifactorial threshold model is proposed in which the disease emerges when thecumulative burden of modifiable risk factors exceeds the brain's compensatory capacity.A novel dimension of this framework concerns the specific vulnerability of the Default Mode Network(DMN) — the brain system responsible for self-referential thought and the continuous internalnarrative — which is Alzheimer's preferential first target. The author presents a first-person casestudy of over seven years of sustained DMN deactivation with preserved cognitive and socialfunctioning, suggesting that cognitive diversification through non-DMN-dependent pathways mayreduce both the metabolic vulnerability of DMN structures and the clinical impact of theirdegradation.The paper proposes a prevention-oriented model combining population-level blood-basedbiomarker screening (p-tau217, GFAP, NfL, amyloid-beta 42/40 ratio) from age 45 with structuredupstream lifestyle intervention — dietary modification, physical activity, sleep optimisation, stressreduction, metabolic health management, and observational awareness training — rather thanpost-symptomatic diagnosis and pharmacological treatment. Ten empirically testable researchquestions are formulated, and an invitation to institutional research collaboration is extended.
Key findings
- This paper presents the Redirection Hypothesis: a framework that reinterprets amyloidaccumulation not as the cause of Alzheimer's disease but as a late-stage downstream consequenceof upstream biological chain failures — in neuroinflammation, epigenetic regulation, mitochondrialfunction, gut-brain si
- The author presents a first-person casestudy of over seven years of sustained DMN deactivation with preserved cognitive and socialfunctioning, suggesting that cognitive diversification through non-DMN-dependent pathways mayreduce both the metabolic vulnerability of DMN structures and the clinical im
Why it matters
The paper proposes the Redirection Hypothesis, which reinterprets amyloid accumulation as a late downstream consequence of upstream biological failures rather than the cause of Alzheimer's disease. It is a research proposal and framework, not a tested treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 26 of the 64 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Zenodo (CERN European Organization for Nuclear Research)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 26 of the 64 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Wijn, M. (2026). Research Proposal Consciousness Mode Alzheimers. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.19692806
Vancouver
Wijn M. Research Proposal Consciousness Mode Alzheimers. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.19692806.
BibTeX
@article{wijn2026-69ec05da,
author = {Wijn, Mart},
title = {{Research Proposal Consciousness Mode Alzheimers}},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
doi = {10.5281/zenodo.19692806},
url = {https://doi.org/10.5281/zenodo.19692806}
}
Related studies in Biomarkers
Also in Biomarkers
119 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.